top of page

Evidence of health treatments efficacy

Examples

Evidence of Health Treatment Efficacy Implementation Guide published by Linca Telecomunicações Ltda. This guide is not an authorized publication; it is the continuous build for version 1.0.0. This version is based on the current content of <link> and changes regularly. See the implementation guide for version fhir r5

Examples

Page standards status: Informative

Evidence


{
    "resourceType": "Evidence",
    "id": "12",
    "meta": {
        "versionId": "2",
        "lastUpdated": "2026-05-12T10:53:35.904-03:00"
    },
    "extension": [
        {
            "url": "https://treatments.telix.health/implementationguide/extensions/study-country",
            "valueCodeableConcept": {
                "coding": [
                    {
                        "system": "https://hl7.org/fhir/ValueSet/country",
                        "code": "CN",
                        "display": "China"
                    }
                ]
            }
        }
    ],
    "identifier": [
        {
            "use": "official",
            "system": "https://interneb.org/global-computable-evidence-identifiers",
            "value": "osteoarthritis-artrodar-pmc9908446"
        }
    ],
    "title": "This Evidence resource describes a clinical study evaluating diacerein-based treatment for knee osteoarthritis.",
    "status": "active",
    "date": "2023-01",
    "publisher": "Linca Telecomunicações Ltda",
    "author": [
        {
            "name": "Diuary Cordeiro Machado",
            "telecom": [
                {
                    "system": "email",
                    "value": "diuarycm@gmail.com"
                }
            ]
        }
    ],
    "useContext": [
        {
            "code": {
                "system": "https://build.fhir.org/ig/HL7/ebm/en/ValueSet-179431.html",
                "code": "population",
                "display": "Population"
            },
            "valueCodeableConcept": {
                "coding": [
                    {
                        "system": "https://icd.who.int/ct/icd11_mms/en",
                        "version": "2026-01",
                        "code": "FA01",
                        "display": "Osteoarthritis"
                    }
                ]
            }
        },
        {
            "code": {
                "system": "https://build.fhir.org/ig/HL7/ebm/en/ValueSet-179431.html",
                "code": "intervention",
                "display": "Intervention"
            },
            "valueCodeableConcept": {
                "coding": [
                    {
                        "system": "https://www.gs1.org/industries/healthcare",
                        "code": "7896281152018",
                        "display": "Artrodar 50 mg, 30 capsules, Brazil"
                    }
                ]
            }
        },
        {
            "code": {
                "system": "https://build.fhir.org/ig/HL7/ebm/en/ValueSet-179431.html",
                "code": "outcome-measure",
                "display": "Outcome Measure"
            },
            "valueCodeableConcept": {
                "coding": [
                    {
                        "system": "https://terminology.hl7.org/7.1.0/en/ValueSet-research-study-purpose-type.html",
                        "code": "efficacy",
                        "display": "Efficacy Study"
                    }
                ]
            }
        }
    ],
    "relatedArtifact": [
        {
            "type": "citation",
            "display": "Zhiyu Wang et al. American Journal of Translational Research, 01 / 2023",
            "document": {
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9908446/",
                "title": "Diacerein plus glucosamine hydrochloride improves the safety and efficacy and inhibit inflammatory factors in the treatment of knee osteoarthritis"
            }
        }
    ],
    "variableDefinition": [
        {
            "description": "Efficacy is calculated as the number of people who had a specific benefit from the treatment divided by the number of people who used or underwent the treatment. The specific benefits are categorized as the code system below.",
            "variableRole": {
                "coding": [
                    {
                        "system": "https://www.hl7.org/fhir/valueset-variable-role.html",
                        "code": "measuredVariable",
                        "display": "Measured Variable"
                    }
                ]
            }
        }
    ],
    "studyDesign": [
        {
            "coding": [
                {
                    "system": "https://hl7.org/fhir/codesystem-study-design.html",
                    "code": "SEVCO:010013",
                    "display": "Case-control studies"
                }
            ]
        }
    ],
    "statistic": [
        {
            "description": "Efficacy calculated based on patients who achieved a persistent reduction in the intensity, frequency, or variety of symptoms with the use of the treatment.",
            "category": {
                "coding": [
                    {
                        "system": "https://treatments.telix.health/codesystem/categorized-efficacy-outcomes",
                        "code": "persistent-reduction",
                        "display": "Persistent reduction of symptoms/indicators"
                    }
                ]
            },
            "numberOfEvents": 55,
            "numberAffected": 35,
            "sampleSize": {
                "numberOfParticipants": 116
            }
        }
    ]
}

Telix Implementation Guide - 2026 - Linca Telecomunicações

bottom of page